Five Prime Therapeutics, Inc. has entered a strategic research collaboration and license agreement with Inhibrx for Inhibrx’s glucocorticoid-induced tumor necrosis factor receptor (GITR) antibody program, currently at lead selection stage.   Five Prime identified GITR as a potent inhibitor of tumor growth using its protein library and in vivo screening technologies. GITR is an immune checkpoint protein believed to activate an immune response against tumor cells. In preclinical studies, a...